Cladribine Venetoclax in Monocytic AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Registration Number
- NCT06232655
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
- Detailed Description
This is an investigator-initiated, open label, single institution, Study to assess the efficacy of Clad/Ven following failure of HMA/Ven in AML with a monocytic phenotype. In cycle 1, subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 and venetoclax 400mg daily (following standard dose escalation over the first 3 days) on days 1 through 28 of a 28 day cycle. A bone marrow biopsy will be performed to assess response on day 28 of cycle 1. Subjects who respond to cycle 1, defined as achieving a CR, CRi, MLFS, or PR per ELN criteria, or a blast reduction of at least 50% from baseline, may continue on alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles). Cycles will continue unless the subject needs to be removed from the study due to disease progression, treatment failure (defined as failure to achieve CR, CRi, or MLFS after 4 cycles of treatment), intolerance or toxicity, patient preference, or other reasons.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
A subject will be eligible for study participation if they meet the following criteria within 28 days prior to the first day of treatment. Historical records are permitted per investigator discretion.
-
Subject must have confirmation of non-acute promyelocytic leukemia (APL) Acute Myeloid Leukemia (AML) by the World Health Organization (WHO) criteria with a monocytic or monoblastic phenotype or a Ras pathway mutation.
-
The subject's AML must be relapsed after or refractory to prior treatment with hypomethylating agent (HMA) and venetoclax combination.
Note: other prior line(s) of therapy including stem cell transplant (SCT) are allowed, but HMA/Ven must be one of the preceding treatments. Subjects who have progressed to AML after prior treatment with HMA/Ven for high grade Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS) are also eligible.
-
Age ≥ 18 years
-
Projected life expectancy of at least 12 weeks
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
-
Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021).
-
Adequate liver function, as demonstrated by:
- Aspartate aminotransferase (AST) ≤ 3.0 x ULN*
- Alanine aminotransferase (ALT) ≤ 3.0 x ULN*
- Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome* *In subjects with Gilbert's syndrome, bilirubin needs to be ≤ 4 x ULN
-
Non-sterile male subjects must use contraceptive methods with partner(s) at least prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. No contraception is required if male subjects are surgically sterile (vasectomy with medical assessment confirming surgical success) or if the male subject has a female partner who is postmenopausal or permanently sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
-
Female subjects must be either:
- Postmenopausal: defined as age > 60 years with no menses for 12 or more months without an alternative medical cause; OR
- Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy); OR
- If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose.
-
Subject must voluntarily sign an informed consent, approved by the Institutional Research Board (IRB), prior to the initiation of any research-related screening or study procedures.
-
Subject has received prior treatment with cladribine for AML.
-
Subject has a white blood cell count > 25 x 109/L. Note: hydroxyurea and/or leukapheresis are permitted to meet this criterion.
-
Subject has known active central nervous system (CNS) involvement of AML.
-
Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal). Uncontrolled is defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment. Patients on antibiotics, antivirals, or antifungals with controlled systemic symptoms will not be excluded.
-
Subject has any clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study, including but not limited to:
- New York Heart Association heart failure > class 2
- Renal, neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia.
-
Subject has a QTc interval > 470 msec.
-
Subject has a history of other malignancies within 2 years prior to study entry, with the following exceptions:
- Adequately treated in situ carcinoma of the breast or cervix
- Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
- Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
- Prostate cancer not requiring therapy beyond hormonal therapy
-
Subject is pregnant or breastfeeding.
-
Subject is known to be positive for HIV. HIV testing is not required.
-
Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required, and subjects with serologic evidence of prior vaccination to HBV may participate.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cladribine plus Venetoclax Cladribine Subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 of a 28 day cycle. Concomitantly, venetoclax will be administered orally at a dose of 100mg on day 1, 200mg on day 2, and 400mg daily on days 3 through 28. Cladribine plus Venetoclax Venetoclax Subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 of a 28 day cycle. Concomitantly, venetoclax will be administered orally at a dose of 100mg on day 1, 200mg on day 2, and 400mg daily on days 3 through 28. Alternating Aza/Ven and Clad/Ven Cladribine Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study. Alternating Aza/Ven and Clad/Ven Azacitidine Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study. Alternating Aza/Ven and Clad/Ven Venetoclax Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study.
- Primary Outcome Measures
Name Time Method Overall response rate (ORR) End of Treatment, an average of 6 months Defined as the proportion of subjects who achieve a CR, CRi, or MLFS that is relapsed after or refractory to HMS/Ven
- Secondary Outcome Measures
Name Time Method Adverse Events Duration of Treatment, an average of 6 months Frequency of adverse events (AEs) and serious adverse events (SAEs)
Event-free survival Minimum of 3 years off study Event-free survival (EFS)
Duration of response minimum of 3 years or off study Duration of response (DOR)
Measurable residual disease Baseline through End of Treatment, an average of 6 months Rate of measurable residual disease (MRD)-negativity
Overall survival minimum of 3 years or off study Overall survival (OS)
Trial Locations
- Locations (1)
Universtiy of Colorado Hospital
🇺🇸Aurora, Colorado, United States